Axogen, Inc. (NASDAQ:AXGN)
| Market Cap | $3.33B+96.4% |
| Revenue (ttm) | $266.93M+24.3% |
| Net Income | -$31.92M-1422.3% |
| EPS | -$0.65-1229.2% |
| Shares Out | 59.73M |
| PE Ratio | n/a |
| Forward PE | 79.01 |
| Dividend | n/a |
| Ex-Dividend Date | Jan 27, 2010 |
| Volume | 876,067 |
| Open | $55.71 |
| Previous Close | $56.35 |
| Day's Range | $55.03 - $56.91 |
| 52-Week Range | $26.92 - $59.72 |
| Beta | 1.15 |
| Analysts | Buy |
| Price Target | $58.13(+4.27%) |
| Earnings Date | Feb 23, 2027 |
About AXGN
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
7 firms rating AXGN in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 23, 2027Earnings report
$AXGN stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of AXGN by members of U.S. Congress
| Donna ShalalaHouse | Sale$1.00K – $15.00K | Jun 24, 2019 |
| Donna ShalalaHouse | Purchase$1.00K – $15.00K | Apr 16, 2019 |
Recently reported changes in AXGN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AXGN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AXGN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
AXGN Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New AXGN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AXGN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AXGN
| IWMiShares Russell 2000 ETF | $79.81M |
| VTIVanguard Morningstar Total Stock Market ETF | $67.06M |
| VXFVanguard Extended Market ETF | $32.93M |
| IWOiShares Russell 2000 Growth ETF | $28.33M |
| SCHASchwab U.S. Small-Cap ETF | $17.20M |
| IHIiShares U.S. Medical Devices ETF | $16.44M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from AXGN’s recent data — informational, not investment advice
What’s Behind the Score
News check: Mixed coverage with neutral momentum discussion offset by valuation concerns; no analyst actions or earnings catalysts reported.
Recent Insider Activity
Insider Score Trend Over Time
-35.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| IBRN | iShares Neuroscience and Healthcare ETF | 4.28% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 3.19% |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 2.20% |
| XHE | State Street SPDR S&P Health Care Equipment ETF | 1.78% |
| SAWS | AAM Sawgrass U.S. Small Cap Quality Growth ETF | 1.24% |
| CTAG | Calamos Timpani Active SMID Growth ETF | 1.06% |
| FESC | First Eagle Small Cap Equity ETF | 0.72% |
| MMSC | First Trust Multi-Manager Small Cap Opportunities ETF | 0.71% |
| FTKI | First Trust Small Cap BuyWrite Income ETF | 0.68% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.59% |
| FYC | First Trust Small Cap Growth AlphaDEX Fund | 0.51% |
| EHLS | Even Herd Long Short ETF | 0.50% |
Weight is the stock’s share of each fund’s holdings.
